Biomet, Inc. today announced the commencement of exchange offers for all of its outstanding 10% Senior Notes due 2017, 10 3/8%/11 1/8% Senior Toggle Notes due 2017 and 11 5/8% Senior Subordinated Notes due 2017, which are not registered under the Securities Act of 1933 (the “Original Notes”) for an equal principal amount of its 10% Senior Notes due 2017, 10 3/8%/11 1/8% Senior Toggle Notes due 2017 and 11 5/8% Senior Subordinated Notes due 2017, respectively, which have been registered under the Securities Act of 1933 (the “Exchange Notes”). The Exchange Notes are substantially identical to the Original Notes, except that the Exchange Notes have been registered under the Securities Act of 1933 and the transfer restrictions, registration rights and provisions for additional interest relating to the Original Notes do not apply to the Exchange Notes.
Biomet will accept for exchange any Original Notes validly tendered and not validly withdrawn prior to the expiration of the exchange offers at 5:00 p.m., New York City time, on Thursday, June 19, 2008, unless the exchange offers are extended or terminated.
The terms of the exchange offers and other information relating to Biomet are set forth in a prospectus dated May 21, 2008. Copies of the prospectus and the related letter of transmittal may be obtained from Wells Fargo Bank, N.A., which is serving as the exchange agent for the exchange offers. Wells Fargo Bank’s address, telephone and facsimile number are as follows:
By Registered and Certified Mail:
Wells Fargo Bank, N.A.
Corporate Trust Operations
MAC N9303-121
P.O. Box 1517
Minneapolis, MN 55480
By Overnight Courier or Regular Mail:
Wells Fargo Bank, N.A.
Corporate Trust Operations
MAC N9303-121
6th & Marquette Avenue
Minneapolis, MN 55479
By Hand Delivery:
Wells Fargo Bank, N.A.
Corporate Trust Services
608 2nd Avenue South
Northstar East Building―12th Floor
Minneapolis, MN 55402
By Facsimile Transmission:
(612) 667-6282
Confirm by Telephone:
(800) 344-5128This press release does not constitute an offer to purchase any securities or the solicitation of an offer to sell any securities. The exchange offers are being made only pursuant to the prospectus dated May 21, 2008 and the related letter of transmittal and only to such persons and in such jurisdictions as is permitted under applicable law.
About Biomet
Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 70 countries.
Forward-Looking Statements
This press release contains certain statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, including those relating to the exchange offers described above, and may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, and the risk factors as set forth in the registration statement relating to the exchange offers. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet’s objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer at (574) 372-1687 or Barbara Goslee, Director, Corporate Communications at (574) 372-1514.
Contacts:
Daniel P. Florin, Senior Vice President and
Chief
Financial Officer, 574-372-1687
or
Barbara Goslee, Director,
Corporate Communications,
574-372-1514
